Cyclosporiasis medical therapy

• • NOTOC**

Cyclosporiasis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Cyclosporiasis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X-Ray
CT Scan
MRI
Ultrasound
Treatment
Medical Therapy
Primary Prevention
Case Studies
Case #1
Cyclosporiasis medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
slides
Images
American Roentgen Ray Society Images of Cyclosporiasis medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Cyclosporiasis medical therapy
on Cyclosporiasis medical therapy
Cyclosporiasis medical therapy in the news
Blogs on Cyclosporiasis medical therapy
Directions to Hospitals Treating Cyclosporiasis
Risk calculators and risk factors for Cyclosporiasis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Joseph Nasr, M.D.[2]; Ammu Susheela, M.D. [3]

Medical therapy

Cyclosporiasis is treated primarily with trimethoprim-sulfamethoxazole (TMP-SMX). Antimicrobial treatment is recommended for symptomatic infection, particularly in patients with prolonged or severe diarrhea, dehydration, weight loss, malabsorption, or immunocompromise. Supportive care, including fluid and electrolyte replacement, is important in patients with clinically significant gastrointestinal losses.

Untreated illness may persist for weeks or longer and may follow a relapsing course. Patients with advanced HIV infection, solid-organ transplantation, or other substantial immunosuppression are at increased risk of severe, prolonged, recurrent, or extraintestinal disease.

Treatment of immunocompetent adults

Trimethoprim-sulfamethoxazole is the preferred treatment for symptomatic cyclosporiasis.

Medication	Dose	Duration	Clinical notes
Trimethoprim-sulfamethoxazole	TMP 160 mg/SMX 800 mg orally twice daily	7-10 days	Preferred regimen for immunocompetent adults.

Clinical improvement generally occurs within several days of effective therapy. Persistent or recurrent symptoms should prompt reassessment for:

• Medication nonadherence or intolerance
• Inadequate hydration
• Reinfection or continued exposure
• An alternative or concurrent gastrointestinal infection
• Malabsorption
• Unrecognized immunosuppression
• A complication such as biliary disease

Supportive care

Supportive management should accompany antimicrobial therapy when clinically indicated.

• Assess volume status and provide oral rehydration or intravenous fluids for clinically significant dehydration.
• Measure and correct clinically relevant electrolyte abnormalities.
• Assess nutritional status in patients with prolonged illness, weight loss, malabsorption, or recurrent diarrhea.
• Provide nutritional supplementation in patients with malnutrition or clinically significant weight loss.
• Consider anti-motility therapy only after excluding dysentery, high fever, severe colitis, toxic megacolon, or another invasive enteric infection.
• Hospitalize patients with severe dehydration, inability to maintain oral intake, severe electrolyte disturbance, hemodynamic instability, severe malabsorption, or serious comorbidity.

Sulfonamide allergy or TMP-SMX intolerance

No alternative regimen has efficacy comparable to TMP-SMX.

The reported allergy should be characterized before excluding TMP-SMX. A history of nausea, isolated gastrointestinal intolerance, or a remote non-severe rash should be distinguished from a severe delayed hypersensitivity reaction.

TMP-SMX rechallenge or desensitization should not be performed in patients with a history of:

• Stevens-Johnson syndrome
• Toxic epidermal necrolysis
• Drug reaction with eosinophilia and systemic symptoms
• Severe hepatitis, nephritis, pneumonitis, or other organ involvement
• Other life-threatening delayed hypersensitivity reactions

In patients with a non-severe allergy or intolerance and a compelling need for treatment, TMP-SMX desensitization may be considered in consultation with allergy/immunology and infectious diseases specialists.

Alternative therapy in adults and adolescents with HIV

The following alternatives apply specifically to adults and adolescents with HIV who cannot receive TMP-SMX.

Alternative	Regimen	Evidence grade	Clinical role
Pyrimethamine plus leucovorin	Pyrimethamine 50-75 mg orally once daily plus leucovorin 10-25 mg orally once daily for 4 weeks	BIII	Preferred alternative in adults and adolescents with HIV who cannot receive TMP-SMX.
Ciprofloxacin	500 mg orally twice daily or 400 mg intravenously twice daily for 7 days	CI	Second-line option when TMP-SMX cannot be used and pyrimethamine is unavailable.

Ciprofloxacin is less effective than TMP-SMX. In a randomized trial involving patients with HIV, ciprofloxacin produced lower clinical and parasitologic response rates than TMP-SMX.

Nitazoxanide has limited and inconsistent evidence and should not be considered an established equivalent alternative to TMP-SMX.

Agents without established efficacy

The following agents should not be used as routine therapy because evidence of benefit is absent, inadequate, inconsistent, or inferior to TMP-SMX:

• Albendazole
• Trimethoprim monotherapy
• Azithromycin
• Metronidazole
• Tinidazole
• Tetracycline
• Doxycycline
• Nalidixic acid
• Quinacrine
• Diloxanide furoate
• Roxithromycin
• Spiramycin

Limited treatment-outcome data exist for some of these agents, including albendazole, doxycycline, roxithromycin, and spiramycin, but none should be considered an established treatment alternative.

Treatment in children

Trimethoprim-sulfamethoxazole is the preferred treatment for cyclosporiasis in children aged 2 months or older.

Population	Regimen	Duration	Notes
Children aged ≥2 months	TMP 5 mg/kg per dose orally twice daily	10 days	Dose is expressed using the trimethoprim component.
Infants aged <2 months	TMP-SMX is generally avoided	—	Sulfonamides may displace bilirubin from albumin and increase the risk of severe neonatal hyperbilirubinemia.

Pediatric infectious diseases consultation should be considered for severe disease, substantial malabsorption, recurrent disease, treatment failure, immunocompromise, or clinically significant sulfonamide hypersensitivity.

Secondary prophylaxis in children with HIV

Secondary prophylaxis may be considered after treatment in children with HIV and severe immunosuppression or recurrent disease.

Regimen	Clinical role
TMP-SMX 2.5 mg/kg of the TMP component orally twice daily, administered 3 days per week	Preferred secondary prophylaxis regimen.
Pyrimethamine 1 mg/kg orally once daily, maximum 25 mg, plus folinic acid 5-15 mg orally once daily	Alternative for patients who cannot receive TMP-SMX.
Ciprofloxacin 10-20 mg/kg orally three times weekly, maximum 500 mg per dose	Second-line alternative.

Treatment during pregnancy

TMP-SMX remains the preferred treatment when antimicrobial therapy is clinically indicated during pregnancy and no equally effective alternative is available. The decision should account for illness severity, gestational age, maternal comorbidity, and the risks of prolonged diarrhea, dehydration, malabsorption, and malnutrition.

Trimethoprim is a folate antagonist. Supplemental folic acid 4 mg/day should be considered in pregnant patients or patients of childbearing potential receiving TMP-SMX (BIII).

In pregnant patients with HIV receiving secondary prophylaxis, withholding prophylaxis during the first trimester and treating only symptomatic infection may be considered when TMP-SMX is not otherwise required for Pneumocystis jirovecii pneumonia prophylaxis (CIII).

Obstetric and infectious diseases consultation is appropriate for:

• Severe or recurrent disease
• Treatment failure
• Advanced HIV infection
• Solid-organ transplantation
• Significant malabsorption
• Severe medication hypersensitivity

Treatment during lactation

TMP-SMX is excreted in breast milk. Current U.S. Food and Drug Administration oral product labeling lists nursing mothers under contraindications because sulfonamides are excreted in milk and may cause kernicterus. Labeling for intravenous TMP-SMX advises avoiding breastfeeding during treatment because of the potential risk of bilirubin displacement and kernicterus.

In contrast, LactMed and clinical lactation references support cautious use in mothers of healthy, full-term infants after the newborn period. TMP-SMX should be avoided during breastfeeding of an infant who is:

• Premature
• Jaundiced
• Acutely ill
• Within the newborn period
• Known or suspected to have glucose-6-phosphate dehydrogenase deficiency

An individualized maternal-infant risk assessment is appropriate when treatment is necessary.

Treatment in adults and adolescents with HIV

TMP-SMX is the preferred treatment for cyclosporiasis in adults and adolescents with HIV. The following recommendations apply specifically to this population.

Clinical setting	Regimen	Evidence grade
Preferred initial treatment	TMP-SMX 160 mg/800 mg orally four times daily for 10 days	AII
Alternative initial treatment	TMP-SMX 160 mg/800 mg orally twice daily for 7 days	BI
Persistent symptoms	Begin with twice-daily TMP-SMX and increase the dose and/or extend treatment for up to 3-4 weeks if symptoms persist	BIII

Intravenous TMP-SMX may be used in patients with potential or documented malabsorption.

Patients with persistent diarrhea should also be evaluated for:

• Other opportunistic enteric infections
• Antiretroviral therapy adherence and virologic control
• CD4 cell count
• Biliary disease
• Severe malabsorption
• Reinfection or continued exposure

Secondary prophylaxis in adults and adolescents with HIV

Secondary prophylaxis is recommended in patients with advanced immunosuppression or substantial risk of recurrence.

Regimen	Evidence grade	Notes
TMP-SMX 160 mg/800 mg orally once daily	AI	Preferred regimen; also provides prophylaxis against Pneumocystis jirovecii pneumonia.
TMP-SMX 320 mg/1600 mg orally three times weekly	BIII	Alternative TMP-SMX schedule.
Pyrimethamine 25 mg orally once daily plus leucovorin 5-10 mg orally once daily	BIII	Alternative when TMP-SMX cannot be used.
Ciprofloxacin 500 mg orally three times weekly	CI	Second-line alternative.

Secondary prophylaxis may be discontinued in patients receiving effective antiretroviral therapy whose CD4 cell count has increased to ≥200 cells/mm³ for more than 6 months (BIII).

Treatment in solid-organ transplant recipients

The following recommendations apply specifically to solid-organ transplant recipients.

Recommendation	Regimen or action	Strength and certainty
Preferred treatment	TMP-SMX 160 mg/800 mg orally four times daily for 10 days, followed by TMP-SMX 160 mg/800 mg orally three times weekly for secondary prophylaxis	Strong recommendation; low-quality evidence
Alternative for sulfonamide intolerance	Ciprofloxacin 500 mg orally twice daily for 7 days, followed by ciprofloxacin 500 mg orally three times weekly for secondary prophylaxis	Weak recommendation; low-quality evidence
Adjustment of immunosuppression	Reduce immunosuppression when clinically feasible	Strong recommendation; very low-quality evidence

The optimal duration of secondary prophylaxis in solid-organ transplant recipients is unknown.

Medication safety and monitoring

Trimethoprim-sulfamethoxazole

Before and during TMP-SMX therapy, assess for:

• Sulfonamide or trimethoprim hypersensitivity
• Baseline renal function
• Volume depletion
• Baseline and follow-up serum potassium when clinically indicated
• Baseline and follow-up blood counts during prolonged or high-dose therapy
• Hepatic dysfunction
• Known or suspected G6PD deficiency
• Clinically important drug interactions

TMP-SMX may cause or contribute to:

• Hyperkalemia
• Increased serum creatinine from inhibition of tubular creatinine secretion
• Acute kidney injury
• Cytopenias
• Hepatitis
• Severe cutaneous adverse reactions
• Hemolysis in patients with G6PD deficiency
• Increased anticoagulant effect of warfarin

The risk of hyperkalemia is increased in patients receiving:

• Angiotensin-converting enzyme inhibitors
• Angiotensin receptor blockers
• Spironolactone
• Potassium supplements
• Other potassium-retaining medications

TMP-SMX dose adjustment is required in clinically significant renal impairment. Specialist guidance should be considered in severe renal dysfunction, severe hepatic disease, previous severe cutaneous adverse reaction, prolonged high-dose treatment, or recurrent disease.

Common pitfalls

• Do not describe Cyclospora oocysts as ova.
• Do not treat ciprofloxacin as equivalent to TMP-SMX.
• Do not present nitazoxanide as an established first-line alternative.
• Do not use the routine pediatric TMP-SMX dose for other infections without confirming the cyclosporiasis-specific recommendation.
• Do not state SMX 25 mg/kg per dose when using the pediatric NIH regimen; the dose should be expressed using the TMP component.
• Do not apply HIV-specific or transplant-specific high-dose regimens to immunocompetent adults.
• Do not omit fluid, electrolyte, and nutritional management in patients with prolonged diarrhea.
• Do not perform TMP-SMX rechallenge or desensitization after a severe delayed hypersensitivity reaction.
• Do not continue indefinite secondary prophylaxis without reassessing immune recovery, recurrence risk, and current guideline criteria.
• Do not use obsolete FDA pregnancy letter categories.